GlassScriptPhysician profile
Reena Bhakta
NPI 1063053254
$11,782.01
in general payments reported to CMS, 2019-2025
35 companies · $5,147 in 2025
The $5,147 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $1,368 · 2024: $5,161 · 2025: $5,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,029.98 |
| Education | $646.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,039.03 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,943.78 | 2023-2025 | |
| Genzyme Corporation | $1,071.07 | 2023-2025 | |
| Leo Pharma INC. | $1,006.61 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $981.54 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $644.31 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $478.12 | 2023-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $452.88 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $427.85 | 2023-2025 | Opzelura |
| Amgen INC. | $312.27 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $290.14 | 2023-2025 | Nemluvio, Aklief |
| Pfizer INC. | $284.35 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.57 | 2023-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $180.94 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $157.54 | 2023-2025 | Olumiant, Taltz, Zepbound |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $153.97 | 2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $125.00 | 2023 | Amvuttra |
| Horizon Therapeutics Plc | $124.50 | 2023 | Tepezza |
| Mayne Pharma Commercial LLC | $122.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $94.46 | 2024-2025 | Sotyktu |
| Alkermes, INC. | $89.14 | 2022 | |
| Ani Pharmaceuticals, INC. | $79.73 | 2024 | Purified Cortrophin Gel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.02 | 2025 | Cabtreo, Jublia, Siliq |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $60.74 | 2023 | Ultomiris, Soliris |
| Fresenius Kabi USA, LLC | $58.06 | 2023-2025 | |
| Biofrontera INC. | $50.23 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $46.59 | 2023-2025 | Hadlima |
| Teva Pharmaceuticals USA, INC. | $29.55 | 2024 | Simlandi |
| Almirall LLC | $27.12 | 2025 | Seysara |
| Lundbeck LLC | $25.57 | 2024 | Vyepti |
| Botanix Sb INC | $21.26 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $21.07 | 2023 | Ycanth |
| Paratek Pharmaceuticals, INC. | $17.20 | 2025 | Nuzyra |
| Boston Scientific Corporation | $15.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Bhakta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.